TruSpine Technolgs. - Notice of Adjourned AGM
Announcement provided by
TruSpine Technologies Plc · TSP21/02/2024 15:57
21 February 2024
TruSpine Technologies plc
("TruSpine" or the "Company")
Notice of Adjourned AGM
TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that notice of the Company's 2022 adjourned annual general meeting ("2022 AGM") has been sent to shareholders today.
The 2022 AGM will be held at Regus, Churchill Court 3,
Certain of the original resolutions have been withdrawn, these resolutions related to the Director's authority to allot new ordinary shares in the Company and the disapplication of pre-emption rights.
A copy of the notice of the 2022 AGM, along with the form of proxy, will be shortly available from the Company's website http://truspine.org/
Enquiries:
TruSpine Technologies Plc |
Tel: +44 (0)20 7118 0852 |
Laurence Strauss, Chief Executive Officer |
|
|
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser) |
Tel: +44 (0)20 7213 0880 |
Liam Murray / Ludovico Lazzaretti |
|
Peterhouse Capital Limited (Broker & Financial Adviser) |
|
Lucy Williams / Duncan Vasey
|
|
Novus Communications (PR and IR) |
Tel: +44 (0)207 448 9839 |
Alan Green / Jacqueline Briscoe |
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.